BERLIN (Reuters) - German diagnostic test maker Qiagen QIA.DE said sales jumped by a bigger-than-expected 26% in the third quarter, boosted by strong demand for its tests for COVID-19.
The company said sales in the July-September period came in at $481.3 million compared with $382.7 million in the year-earlier period and ahead of its forecast for third-quarter sales growth of 16-21% at constant exchange rates.
It said preliminary adjusted earnings per share rose 61% to $0.58 cents at the top end of its forecast for $0.52-$0.58 cents.
Qiagen is due to report full results for the third quarter on Nov. 4.
Reporting by Caroline Copley; Editing by Maria Sheahan
Our Standards: The Thomson Reuters Trust Principles.